Dyne Therapeutics, Inc. Comprehensive Income
Dyne Therapeutics, Inc. (DYN) reported Comprehensive Income of -$178.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-29
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$178.77M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$121.47M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$111.98M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$107.80M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$445.75M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$317.41M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$235.37M.
- Dyne Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$168.40M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$178.77M 10-Q · filed 2026-07-29 | -$300.24M 10-Q · filed 2026-07-29 | -$412.21M derived: sum of 3 quarters · filed 2026-07-29 | -$520.01M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$121.47M 10-Q · filed 2026-05-11 | -$233.44M derived: sum of 2 quarters · filed 2026-05-11 | -$341.24M derived: sum of 3 quarters · filed 2026-05-11 | -$452.08M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$111.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$219.77M derived: sum of 2 quarters · filed 2026-03-02 | -$330.62M derived: sum of 3 quarters · filed 2026-07-29 | -$445.75M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$107.80M 10-Q · filed 2025-11-05 | -$218.64M derived: sum of 2 quarters · filed 2026-07-29 | -$333.77M 10-Q · filed 2025-11-05 | -$423.78M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$110.85M 10-Q · filed 2026-07-29 | -$225.97M 10-Q · filed 2026-07-29 | -$315.99M derived: sum of 3 quarters · filed 2026-07-29 | -$412.39M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$115.13M 10-Q · filed 2026-05-11 | -$205.14M derived: sum of 2 quarters · filed 2026-05-11 | -$301.55M derived: sum of 3 quarters · filed 2026-05-11 | -$366.76M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$90.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$186.42M derived: sum of 2 quarters · filed 2026-03-02 | -$251.63M derived: sum of 3 quarters · filed 2026-03-02 | -$317.41M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$96.41M 10-Q · filed 2025-11-05 | -$161.62M derived: sum of 2 quarters · filed 2025-11-05 | -$227.40M 10-Q · filed 2025-11-05 | -$294.02M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$65.21M 10-Q · filed 2025-07-28 | -$130.99M 10-Q · filed 2025-07-28 | -$197.62M derived: sum of 3 quarters · filed 2026-03-02 | -$257.78M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$65.78M 10-Q · filed 2025-05-08 | -$132.41M derived: sum of 2 quarters · filed 2026-03-02 | -$192.57M derived: sum of 3 quarters · filed 2026-03-02 | -$257.33M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$66.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$126.79M derived: sum of 2 quarters · filed 2026-03-02 | -$191.55M derived: sum of 3 quarters · filed 2026-03-02 | -$235.37M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$60.17M 10-Q · filed 2024-11-12 | -$124.92M derived: sum of 2 quarters · filed 2024-11-12 | -$168.74M 10-Q · filed 2024-11-12 | -$207.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$64.75M 10-Q · filed 2024-08-12 | -$108.57M 10-Q · filed 2024-08-12 | -$146.99M derived: sum of 3 quarters · filed 2025-02-27 | -$188.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$43.82M 10-Q · filed 2024-05-02 | -$82.23M derived: sum of 2 quarters · filed 2025-02-27 | -$123.45M derived: sum of 3 quarters · filed 2025-02-27 | -$175.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$38.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$79.63M derived: sum of 2 quarters · filed 2025-02-27 | -$132.16M derived: sum of 3 quarters · filed 2025-02-27 | -$168.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$41.21M 10-Q · filed 2023-10-30 | -$93.74M derived: sum of 2 quarters · filed 2023-10-30 | -$129.99M 10-Q · filed 2023-10-30 | -$182.01M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | -$52.53M 10-Q · filed 2023-08-03 | -$88.77M 10-Q · filed 2023-08-03 | -$140.79M derived: sum of 3 quarters · filed 2023-08-03 | -$183.37M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$36.24M 10-Q · filed 2023-05-11 | -$88.27M derived: sum of 2 quarters · filed 2023-05-11 | -$130.84M derived: sum of 3 quarters · filed 2023-05-11 | -$160.77M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$52.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$94.60M derived: sum of 2 quarters · filed 2023-03-02 | -$124.52M derived: sum of 3 quarters · filed 2023-03-02 | -$149.53M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$42.58M 10-Q · filed 2022-11-03 | -$72.50M derived: sum of 2 quarters · filed 2022-11-03 | -$97.51M 10-Q · filed 2022-11-03 | -$126.19M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$29.93M 10-Q · filed 2022-08-04 | -$54.94M 10-Q · filed 2022-08-04 | -$83.61M derived: sum of 3 quarters · filed 2022-08-04 | -$97.53M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$25.01M 10-Q · filed 2022-05-02 | -$53.69M derived: sum of 2 quarters · filed 2022-05-02 | -$67.61M derived: sum of 3 quarters · filed 2022-05-02 | -$76.59M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | -$28.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$42.60M derived: sum of 2 quarters · filed 2022-03-10 | -$51.58M derived: sum of 3 quarters · filed 2022-03-10 | -$59.46M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$13.92M 10-Q · filed 2021-11-04 | -$22.90M derived: sum of 2 quarters · filed 2021-11-04 | -$30.79M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$8.98M 10-Q · filed 2021-08-05 | -$16.87M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$7.89M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$14.86M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |